Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Terminated 2Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Glioma 1Brain Neoplasms 1

Interventions

Cytarabine 85Cyclophosphamide 58Azacitidine 57fludarabine 52venetoclax 41fludarabine phosphate 41Busulfan 30Filgrastim 23Whole-Body Irradiation 22Decitabine 21Mycophenolic Acid 20Methotrexate 19Mitoxantrone 18Etoposide 18Antilymphocyte Serum 18Cyclosporine 17Clofarabine 17Tacrolimus 16Granulocyte Colony-Stimulating Factor 16Peripheral Blood Stem Cell Transplantation 15Daunorubicin 15Melphalan 13thymoglobulin 11Thiotepa 11Stem Cell Transplantation 11Interleukin-2 11Idarubicin 10Gemtuzumab 9Cord Blood Stem Cell Transplantation 9aldesleukin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Leukemia, Myeloid, Acute × Levetiracetam × Clear all
NCT01685411 2021-04-13

Busulfan and Cyclophosphamide Followed By ALLO BMT

Masonic Cancer Center, University of Minnesota

Phase NA Terminated
5 enrolled 16 charts
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01464359 2017-12-28

T-Cell Depleted Double UCB for Refractory AML

Masonic Cancer Center, University of Minnesota

Phase 2 Terminated
3 enrolled 9 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡